9
/l, and lymphocytes and CD34-positive cells varied in parallel, with lymphocytes between 1.6 Â 10 9 and 7.9 Â 10 9 /l and CD34-positive cells between o1 and 120 Â 10 3 /ml. The platelet count varied inversely between 136 and 370 Â 10 9 /l. Haemoglobin varied between 6.8 and 8.8 mmol/l (Figure 2) .
At 2 years after diagnosis the patient experienced fatigue, fever and night sweats and had enlarged axillary and inguinal glands, and enlarged glands in relation to the left iliac vessels. The bone marrow showed chronic phase CML. Cytogenetic analysis including FISH for BCR-ABL showed no change. Histological and immunological examination of a lymph node was compatible with lymphoblastic lymphoma of the T-cell type. The tumour cells were positive for CD3, CD5, Mib1 and TdT. FISH analysis of the lymph node tissue showed BCR-ABL positivity in most of the cells. In many cells, two fusion signals were found, compatible with the transformed cells having the same variant Ph translocation as the marrow cells (Figure 1b) .
BCR-ABL fusion-transcripts were measured by real-time quantitative PCR as previously described, 2 but the levels of BCR-ABL were related to the 'house keeping' transcript betaglucuronidase (GUS) instead of BCR. 3 The actual ratio BCR-ABL (b2a2 þ b3a2)/GUS was 0.99 in blood and 1.66 in lymph node tissue, respectively. In blood, the ratio between b3a2 and b2a2 was 0.92 while b3a2 was expressed at a level 260 times higher compared with b2a2 in lymph node tissue at transformation.
The patient was started on treatment with imatinib 600 mg daily. After 3 weeks, he was clinically well without lymphadenopathy and after 5 weeks he was in complete haematologic remission. After 2 weeks, treatment with imatinib was temporarily stopped because of grade III nonhaematologic toxicity. A week later, imatinib was restarted at 400 mg daily with no recurrence of side effects. No evident cyclical changes in peripheral blood counts were seen during imatinib treatment. A major cytogenetic response (5% Ph þ cells, 1/20 metaphases) was obtained after 6 months. However, complete cytogenetic remission was not obtained after 2 years and the dose of imatinib was increased to 600 mg daily which led to complete cytogenetic remission. The ratio BCR-ABL/GUS in peripheral blood after 35 months treatment with imatinib was 1.6 Â 10 À4 , an almost 4 log reduction compared with the level at diagnosis. Only b3a2 transcripts were found at this time, while b2a2 transcripts were below the level of detection.
The patient is still in complete clinical, haematologic and cytogenetic remission 39 þ months following start of treatment with imatinib.
The reported patient had spontaneous oscillation in peripheral blood neutrophil and lymphocyte counts, CD34-positive cells and platelet counts, indicating deregulation at the stem cell level. The mechanisms involved are largely unknown but abnormal responses to growth factors or accelerated cell loss through apoptosis may play an important role. Cycling was noted also during treatment with hydroxyurea but was no longer evident during treatment with imatinib. Cyclic changes in blood counts have been described in CML and it is well known that hydroxyurea does not abolish spontaneous oscillation in blood counts whereas treatment with noncell-cycle-specific drugs may abolish cycling.
At the time of nodal transformation, the marrow morphology was compatible with chronic phase CML. In 10 of 26 reported patients with T-lymphoblastic transformation of CML, a predominant extramedullary component was found. 4 Treatment of lymphoid blast crisis in CML with imatinib has resulted in complete haematologic response in 20%, but most responders relapse quickly. This is a report of the first patient with isolated nodal T-cell lymphoid blast crisis treated with imatinib. The patient is in complete clinical, haematologic and cytogenetic remission following 39 þ months treatment. A case of relapsed T-cell lymphoid blast crisis of CML affecting both marrow and lymph nodes has recently been described. This patient also obtained a durable complete response on imatinib (26 þ months). 1 In the present patient, low levels of BCR-ABL can still be detected in peripheral blood. In newly diagnosed patients with CML (treated with imatinib or interferon-a þ Ara-C) who achieved a complete cytogenetic response, undetectable levels of BCR-ABL transcripts were only seen in four per cent of patients during the first 18 month's follow up. 5 Of special interest, the reported patient had two BCR-ABL fusion genes in each cell located at 9q34. Five similar Phnegative cases with double BCR-ABL fusion genes have been published previously; [6] [7] [8] [9] three were in chronic phase, 6, 8 two were in myeloid blast crisis. 7, 9 The described variant Phtranslocation could be the result of either an insertion of the 5 0 part of the BCR gene within or at the 5 0 side of the ABL gene on chromosome 9 or by two successive translocations, a classic t(9;22) followed by a second translocation between both derivatives 9q þ and 22qÀ, masking the first chromosomal exchange. In two patients, FISH results indicated that the former mechanism was involved 6,7 although the latter mechanism could not be completely ruled out. 6 For one patient, it was shown that duplication of the BCR/ABL fusion gene occurred by mitotic recombination of part of chromosome 9.
6 Interestingly, one of the patients in chronic phase had highly variable leukocyte counts, which were difficult to stabilise with hydroxyurea. However it is not described whether the patient had cyclic leukocytosis. 6 None of the previously reported patients were treated with imatinib.
A different splicing pattern for the BCR-ABL transcripts was observed between peripheral blood dominated by myeloid cells expressing equal amounts of b2a2 and b3a2 transcripts, and Tlymphoblasts in lymph node tissue almost exclusively expressing b3a2. To our knowledge, a heterogeneous expression of alternatively spliced BCR-ABL fusion transcripts in different cell types has not been previously described. It is well known that splice-site selection can be determined by the cell in a tissuespecific manner. The different splicing pattern observed might represent tissue-specific regulation of splicing of the BCR/ABL mRNA. It is unknown if the alternative expression of 
Figure 2
Haemoglobin (hgb), peripheral blood counts and CD34-positive cells in peripheral blood during the course of the disease. Spontaneous oscillations are seen before treatment with imatinib. Treatment with hydroxyurea is shown by the box marked H. Treatment with imatinib is shown by boxes marked I. Dotted boxes correspond to imatinib 600 mg daily, while the white box corresponds to 400 mg daily. Asterisk marks treatment with G-CSF for four days before autologous peripheral stem cell harvest.
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